# Actionable druggable genome-wide Mendelian randomization identifies repurposing

#### opportunities for COVID-19 2

- Liam Gaziano<sup>1,2</sup>, Claudia Giambartolomei<sup>3,4</sup>, Alexandre C Pereira<sup>5,6</sup>, Anna Gaulton<sup>7</sup>, Daniel C 4
- Posner<sup>1</sup>, Sonja A Swanson<sup>8</sup>, Yuk-Lam Ho<sup>1</sup>, Sudha K Iyengar<sup>9,10</sup>, Nicole M Kosik<sup>1</sup>, Marijana 5
- Vujkovic<sup>11,12</sup>, David R Gagnon<sup>13,1</sup>, A Patrícia Bento<sup>7</sup>, Pedro Beltrao<sup>14</sup>, Inigo Barrio-Hernandez<sup>14</sup>, 6
- Lars Rönnblom<sup>15</sup>, Niklas Hagberg<sup>15</sup>, Christian Lundtoft<sup>15</sup>, Claudia Langenberg<sup>16,17</sup>, Maik 7
- Pietzner<sup>17</sup>, Dennis Valentine<sup>18,19</sup>, Elias Allara<sup>2</sup>, Praveen Surendran<sup>2,20,21,22</sup>, Stephen Burgess<sup>23,2</sup>, 8
- Jing Hua Zhao<sup>2</sup>, James E Peters<sup>24,25</sup>, Bram P Prins<sup>2,21</sup>, John Danesh<sup>2</sup>, Poornima Devineni<sup>1</sup>, 9
- Yunling Shi<sup>1</sup>, Kristine E Lynch<sup>26,27</sup>, Scott L DuVall<sup>26,27</sup>, Helene Garcon<sup>1</sup>, Lauren O Thomann<sup>1</sup>, 10
- Jin J Zhou<sup>28,29</sup>, Bryan R Gorman<sup>1</sup>, Jennifer E Huffman<sup>30</sup>, Christopher J O'Donnell<sup>31,32</sup>, Philip S 11
- Tsao<sup>33,34</sup>, Jean C Beckham<sup>35,36</sup>, Saiju Pyarajan<sup>1,37</sup>, Sumitra Muralidhar<sup>38</sup>, Grant D Huang<sup>38</sup>, 12
- Rachel Ramoni<sup>38</sup>, Adriana M Hung<sup>39,40</sup>, Kyong-Mi Chang<sup>41,42</sup>, Yan V Sun<sup>43,44</sup>, Jacob Joseph<sup>45,1</sup>, 13
- Andrew R Leach<sup>7</sup>, Todd L Edwards<sup>46,47</sup>, Kelly Cho<sup>1,48</sup>, J Michael Gaziano<sup>1,48</sup>, Adam S 14
- Butterworth<sup>2,20,21,49,50</sup>, Juan P Casas<sup>1,48</sup> on behalf VA Million Veteran Program COVID-19 15
- Science Initiative 16

1

3

17

- <sup>1</sup>Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA 18
- 19 Boston Healthcare System, Boston, MA, USA
- <sup>2</sup>BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, 20
- University of Cambridge, Cambridge, UK 21
- <sup>3</sup>Central RNA Lab, Istituto Italiano di Tecnologia, Genova, Italy 22
- 23 <sup>4</sup>Department of Pathology and Laboratory Medicine, David Geffen School of Medicine,
- University of California Los Angeles, Los Angeles, CA, USA 24
- <sup>5</sup>Laboratory of Genetics and Molecular Cardiology, Heart Institute, University of Sao Paulo, Sao 25
- Paulo, Brazil 26
- <sup>6</sup>Genetics Department, Harvard Medical School, Harvard University, Boston, MA, USA 27
- <sup>7</sup>Chemical Biology, European Molecular Biology Laboratory, European Bioinformatics Institute, 28
- Hinxton, UK 29
- <sup>8</sup>Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands 30
- <sup>9</sup>Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA 31
- 32 <sup>10</sup>Department of Population and Quantitative Health Sciences, Case Western Reserve University
- and Louis Stoke, Cleveland VA, Cleveland, OH, USA 33
- <sup>11</sup>The Corporal Michael J. Crescenz VA Medical Center, the University of Pennsylvania 34
- Perelman School of Medicine, Philadelphia, PA, USA 35
- <sup>12</sup>Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 36
- <sup>13</sup>Biostatistics, School of Public Health, Boston University, Boston, MA, USA 37
- <sup>14</sup>European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, UK 38

- 39 <sup>15</sup>Department of Medical Sciences, Uppsala University, Uppsala, Sweden
- 40 <sup>16</sup>Berlin Insitute of Health, Charité University Medicine Berlin, Berlin, Germany
- 41 <sup>17</sup>MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
- 42 <sup>18</sup>Institute of Health Informatics, University College London, London, UK
- 43 <sup>19</sup>Health Data Research, University College London, London, UK
- 44 <sup>20</sup>British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge,
- 45 UK
- 46 <sup>21</sup>Health Data Research UK Cambridge, Wellcome Genome Campus and University of
- 47 Cambridge, Cambridge, UK
- 48 <sup>22</sup>Rutherford Fund Fellow, Department of Public Health and Primary Care, University of
- 49 Cambridge, Cambridge, UK
- 50 <sup>23</sup>MRC Biostatistics Unit, University of Cambridge, Cambridge, UK
- 51 <sup>24</sup>Centre for Inflammatory Disease, Dept of Immunology and Inflammation, Imperial College,
- 52 London, UK
- 53 <sup>25</sup>Health Data Research UK, UK
- 54 <sup>26</sup>VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt
- 55 Lake City, UT, USA
- 56 <sup>27</sup>Department of Internal Medicine, Epidemiology, University of Utah, Salt Lake City, UT, USA
- 57 <sup>28</sup>Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA
- 58 <sup>29</sup>Phoenix VA Health Care System, Phoenix, AZ, USA
- 59 <sup>30</sup>Center for Population Genomics, Massachusetts Veterans Epidemiology Research and
- 60 Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA
- 61 <sup>31</sup>Cardiology, VA Boston Healthcare System, Boston, MA, USA
- 62 <sup>32</sup>Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 63 <sup>33</sup>Epidemiology Research and Information Center (ERIC), VA Palo Alto Health Care System,
- 64 Palo Alto, CA, USA
- 65 <sup>34</sup>Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA
- 66 <sup>35</sup>MIRECC, Durham VA Medical Center, Durham, NC, USA
- 67 <sup>36</sup>Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine,
- 68 Durham, NC, USA
- 69 <sup>37</sup>Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 70 <sup>38</sup>Office of Research and Development, Department of Veterans Affairs, Washington, DC, USA
- 71 <sup>39</sup>VA Tennessee Valley Healthcare System, Nashville, TN, USA
- 72 <sup>40</sup>Nephrology & Hypertension, Vanderbilt University, Nashville, TN, USA
- 73 <sup>41</sup>The Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA
- 74 <sup>42</sup>Department of Medicine, Perlman School of Medicine, University of Pennsylvania,
- 75 Philadelphia, PA, USA
- 76 <sup>43</sup>Atlanta VA Health Care System, Decatur, GA, USA
- 77 <sup>44</sup>Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA,
- 78 USA

- <sup>45</sup>Medicine, Cardiovascular, VA Boston Healthcare System and Brigham & Women's Hospital,
   Boston, MA, USA
   <sup>46</sup>Department of Veterans Affairs, Tennessee Valley Healthcare System, Vanderbilt University,
- 82 Nashville, TN, USA
- 83 <sup>47</sup>Medicine, Epidemiology, Vanderbilt Genetics Institute, Vanderbilt University Medical Center,
- 84 Nashville, TN, USA
- 85 <sup>48</sup>Division of Aging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA,
- 86 USA

91 92

97

- 87 <sup>49</sup>National Institute for Health Research Blood and Transplant Research Unit in Donor Health
- and Genomics, University of Cambridge, Cambridge, UK
- 89 <sup>50</sup>National Institute for Health Research Cambridge Biomedical Research Centre, University of
- 90 Cambridge and Cambridge University Hospitals, Cambridge, UK
- 93 **Authors for correspondence:** <u>asb38@medschl.cam.ac.uk</u> (A.S.B.),
- 94 jpcasasromero@bwh.harvard.edu (J.P.C.)
- 95 **Key words:** Mendelian randomization, drug repurposing, COVID-19, actionable druggable
- 96 genome

# Abstract

Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address COVID-19. To identify therapeutic targets relevant to COVID-19, we conducted Mendelian randomization (MR) analyses, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development. Using summary statistics from the Host Genetics Initiative and the Million Veteran Program, we studied 7,554 patients hospitalized with COVID-19 and >1 million controls. We found significant Mendelian randomization results for three proteins (ACE2:  $P=1.6\times10^{-6}$ , IFNAR2:  $P=9.8\times10^{-11}$ , and IL-10RB:  $P=1.9\times10^{-14}$ ) using *cis*-eQTL genetic instruments that also had strong evidence for colocalization with COVID-19 hospitalization. To disentangle the shared eQTL signal for *IL10RB* and *IFNAR2*, we conducted phenome-wide association scans and pathway enrichment analysis, which suggested that *IFNAR2* is more likely to play a role in COVID-19 hospitalization. Our findings prioritize trials of drugs targeting IFNAR2 and ACE2 for early management of COVID-19.

INTRODUCTION

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

COVID-19 has caused a global pandemic resulting in excess mortality, stress on healthcare systems and economic hardship. Even if an efficacious vaccine against SARS-CoV-2 virus emerges in 2021, it could take several years to achieve herd immunity. Hence, there is a need to rapidly identify drugs that can minimize the burden of COVID-19. Although large randomized trials have begun to successfully identity drugs that can be repurposed to address COVID-19. 1,2 most drugs evaluated so far have failed to show efficacy and have been largely confined to hospitalized or critically-ill patients. Therefore, it is pressing to identify additional drugs that can be repurposed for early management in COVID-19. Large-scale human genetic studies are now widely used to inform drug development programs as drug target-disease pairs supported by human genetics have a greater odds of success in drug discovery pipelines.<sup>3,4</sup> For example, identification of variants in *PCSK9* associated with lower risk of coronary disease led to the successful development of PCSK9 inhibitors, which are now licensed for prevention of cardiovascular events.<sup>5</sup> The value of human genetics for drug discovery and development has also been realized for infectious diseases. Human genetic studies showed that genetic variation in the CCR5 gene provides protection against infection by human immunodeficiency virus (HIV) type-1. These findings were key for the development of Maraviroc, an antagonist of CCR5, approved by the FDA for the treatment of patients with HIV-1.6 Genetic variants acting in "cis" on druggable protein levels or gene expression that encode druggable proteins can provide powerful tools for informing therapeutic targeting, as they mimic

the on-target (beneficial or harmful) effects observed by pharmacological modification. Such Mendelian randomization (MR) analyses have been used to suggest repurposing opportunities for licensed drugs. MR analysis that focuses on actionable druggable genes, defined as genes that encode the protein targets of drugs that are licensed or in the clinical phase of drug development, could therefore serve as a fast and robust strategy to identify drug-repurposing opportunities to prevent the complications and mortality due to COVID-19.

To identify further potential repurposing opportunities to inform trials of COVID-19 patients, we conducted large-scale MR and colocalization analyses using gene expression and soluble protein data for 1,263 actionable druggable genes that encode protein targets for approved drugs or drugs in clinical development. By combining trans-ancestry genetic data from 7,554 hospitalized COVID-19 patients and more than 1 million population-based controls from the COVID-19 Host Genetics Initiative (HGI) and the Million Veteran Program (MVP), we provide support for two therapeutic strategies.

# **RESULTS**

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

# Overall analysis plan

**Figure 1** describes the overall scheme of the analyses. First, we identified all proteins that are therapeutic targets of approved or clinical-stage drugs. Next, we selected conditionallyindependent genetic variants that act locally on plasma levels of these proteins or tissue-specific gene expression that encode these proteins. We proposed that these variants were instrumental variables and conduct two-sample MR analyses<sup>12</sup> using a trans-ancestry meta-analysis of 7,554 cases from MVP and publicly available data (HGI outcome B2 from release 4 version 1, downloaded October 4<sup>th</sup> 2020, **Supplementary Table 1**). Given that all MR analyses relies on several assumptions, some<sup>13</sup> unverifiable, we conducted a multi-stage strategy to minimize confounding and biases. For MR results that passed our significance threshold after accounting for multiple testing, we performed colocalization to ensure MR results were not due to confounding by linkage disequilibrium (LD). Those with evidence of colocalization were investigated further using an independent proteomics platform (Olink). Finally, we conducted phenome-wide scans and pathway enrichment of relevant variants to reduce risks of horizontal pleiotropy and other biases due to MR violations as well as to understand potential biological mechanisms.

### **Actionable druggable proteins**

Using data available in ChEMBL version 26, we identified 1,263 human proteins as 'actionable' (i.e. therapeutic targets of approved or clinical-stage drugs) (**Supplementary Table 2**). Of these, we noted 700 proteins that are targets for drugs with potential relevance to COVID-19 from cell-based screening, registers of clinical trials against COVID-19 or approved immunomodulatory/anticoagulant drugs (given the clear role of these pathways in COVID-19

outcomes), or have biological evidence for the role of the protein in SARS-CoV-2 infection (Supplementary Table 3).

# Genetic proposed instruments for actionable druggable proteins

Using GTEx version 8 (V8)<sup>14</sup>, we identified all conditionally-independent expression quantitative trait loci (eQTLs) in 49 tissues that act in *cis* (within 1 Mb on either side of the encoded gene), that covered 1,016 of the 1,263 druggable genes in at least one tissue (**Supplementary Table 2 and 4**). We also selected *cis*-pQTLs for plasma proteins measured using the SomaScan platform in 3,301 participants of the INTERVAL study<sup>15</sup> (**Supplementary Table 5**) and 10,708 Fenland cohort participants<sup>16</sup> (**Supplementary Table 6**) that covered a total of 67 proteins. In total 1,021 proteins had genetic proposed instruments using either eQTLs or pQTLs, and 62 had proposed instruments using both.

### Mendelian randomization and colocalization

Using our (eQTL and pQTL) proposed instruments, we performed two-sample MR on transancestry summary statistics for hospitalized COVID-19 cases from MVP and HGI (**Supplementary Table 1**). Using GTEx cis-eQTLs as proposed instruments, we found significant (P<4.0×10<sup>-5</sup>, 0.05 Bonferroni-corrected for 1,263 proteins) MR results for six genes (IL10RB, CCR1, IFNAR2, PDE4A, ACE2 and CCR5) in at least one tissue (**Table 1**), and four additional genes (CA5B, CA9, NSTN and SLC9A3) with suggestive MR results (P<5×10<sup>-4</sup> and P>4×10<sup>-5</sup>, **Figure 2**). No proposed instruments involving cis-pQTLs reached our suggestive threshold in any of the analyses. For three significant genes (IL10RB, IFNAR2, ACE2) there was strong evidence of colocalization (posterior probability of shared causal variant across two traits

- hypothesis 4 [PP.H4] >0.8) between at least one proposed instrumental variant and our transancestry meta-analysis of COVID-19 hospitalization (**Table 1**). Beta-coefficients of MR estimates for *ACE2* were positive in all tissues (**Table 1**), meaning higher *ACE2* expression is associated with higher risk of COVID-19 hospitalization. MR beta-coefficients for *IFNAR2* and *IL10RB* were negative and positive, respectively, in all tissues except one for each gene (skeletal muscle for *IFNAR2*; cultured fibroblasts for *IL10RB*; **Table 1**).

# **IL10RB and IFNAR2**

Interferon alpha receptor 2 (IFNAR2) and interleukin 10 receptor beta (IL-10RB) both act as receptors for interferons (IFN). IFNAR2 forms a complex with IFNAR1, which together act as a receptor for type I IFN (IFN- $\alpha$ ,  $\beta$ ,  $\omega$ ,  $\kappa$ ,  $\varepsilon$ ), while IL-10RB acts as a receptor for type III IFN (IFN- $\lambda$ ) when complexed with interferon lambda receptor-1 (IFNLR1)<sup>17</sup>, or IL-10 when complexed with IL-10RA. IL-10RB and IFNAR2 are encoded by adjacent genes and some *cis*-eQTLs for *IL10RB* are also *cis*-eQTLs for *IFNAR2* (**Supplementary Table 7, Figure 3**), making it difficult to determine which gene may be responsible for the association with COVID-19 and requiring further investigation.

All significant MR results for IFNAR2/IL10RB that colocalized with COVID-19 hospitalization contained one of nine strongly correlated ( $r^2>0.75$  in 1000G European ancestry participants) variants (rs11911133, rs1051393, rs2300370, rs56079299, rs17860115, rs13050728, rs2236758, rs12053666, and rs1131668), which are cis-eQTLs for IL10RB in eleven tissues and for IFNAR2 in four tissues (**Supplementary Table 8**). Within this LD block (hereafter rs13050728-LD block), rs13050728 is the eQTL most strongly associated with COVID-19 hospitalization (per T-

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

allele odds ratio = 1.17; 95% CI = 1.12-1.23;  $P=1.88\times10^{-12}$ ; Supplementary Table 7). Variants outside the rs13050728-LD block were not strongly associated with COVID-19 hospitalization (Figure 3). pQTLs for IL10RB Using stepwise conditional analysis on Olink measurements of plasma IL-10RB we identified two cis-pQTLs, rs2266590 ( $P=1.04\times10^{-136}$ ) and rs2239573 ( $P=2.66\times10^{-19}$ ), which explained 5.4% and 1.2%, respectively, of the variance in plasma IL-10RB. rs2266590 was also an eQTL for IL10RB in three tissues and IFNAR2 in one tissue, while rs2239573 was also an eOTL for IL10RB in two tissues (Supplementary Table 8). rs2266590 and rs2239573 lie in intron 5 and 1, respectively, of the IL10RB gene and are located in separate regions of high epigenetic modification (h3k27ac marking), indicating enhancer regions (Figure 3). rs2266590 and rs2239573 were not associated with COVID-19 hospitalization (P= 0.85 for rs2266590, P=0.66 for rs2239573. **Supplementary Figure 1**) and MR using these two *cis*-pOTLs yields a null result (P=0.74).A third cis-pOTL (rs2834167, P=1.1×10<sup>-8</sup>) for plasma IL-10RB measured on the SomaScan platform was previously identified in 3,200 Icelanders over the age of 65.18 rs2834167 is a missense variant (Lys>Glu) and is not correlated with either of the cis-pQTLs for plasma IL-10RB measured by Olink ( $r^2$ =0.01 for rs2266590,  $r^2$ =0.03 for rs2239573 in 1000G EUR). Although rs2834167 was associated with *IL10RB* expression in 18 tissues, it was not associated with IFNAR2 expression in any tissue (Supplementary Table 8). The A allele at rs2834167, which is associated with lower IL10RB gene expression but higher plasma IL-10RB, was

inversely associated with COVID-19 (per-A-allele OR= 0.91; 95%CI= 0.87-0.95; *P*=5.3×10<sup>-5</sup>). Because Emilsson et al.<sup>18</sup> did not report full summary statistics we could not perform colocalization between this pQTL and COVID-19 hospitalization. However, rs2834167 as an eQTL does not colocalize (PP.H4<0.8) with COVID-19 in any tissue (**Table 1**). These three *cis*-pQTLs, while possibly functional variants altering plasma IL-10RB levels, suggest that the plasma IL-10RB levels are not likely the mediator of the association between this locus and COVID-19 hospitalization. This suggests the MR assumption are unlikely to hold for IL10RB. IFNAR2 was not measured on the SomaScan or Olink platforms.

Phenome-wide scan of rs13050728

To identify other phenotypes associated with rs13050728, we performed a phenome-wide scan of publicly available data on PhenoScanner<sup>19</sup> and GTEx, and unpublished proteomic data in INTERVAL (see methods). rs13050728 was associated with tryptase gamma 1 (TPSG1, P=  $1.5 \times 10^{-5}$ ) and vascular endothelial growth factor 2 (VEGFR2, P=  $2.6 \times 10^{-5}$ , **Supplementary Table 9**), and both showed strong evidence of colocalization with COVID-19 hospitalization (PP.H4=0.96 for VEGFR2, PP.H4=0.96 for TPSG1, **Figure 4**). The C allele at rs13050728 associated with higher *IFNAR2* expression in all tissues (except skeletal muscle), lower risk of COVID-19 hospitalization, and lower levels of plasma VEGFR2 and TPSG1 (**Supplementary Table 9**). This mimics agonistic effects of IFNAR2 through recombinant type-I IFNs, which are known to have an anti-angiogenic effect, at least in part through reduced VEGF/VEGFR2 signaling<sup>20,21</sup>, and decrease tryptase levels in a phase-2 trial using recombinant type-I IFN in patients with mastocytosis<sup>22</sup>, a condition that causes proliferation of mast cells. rs13050728 was not associated at P<4×10<sup>-5</sup> (our Bonferroni corrected P value) with any phenotype beyond

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

plasma VEGFR2 and TPSG1 and gene expression of IFNAR2 and IL10RB (Supplementary **Table 9**), indicating that this variant is unlikely to exhibit widespread horizontal pleiotropy. Also, the chances of substantial bias due to MR violations is low<sup>23</sup> since the variant is not strongly associated with other risk factors that could alter the likelihood of SARS-CoV-2 testing or hospitalization of COVID-19 patients. Pathway enrichment analysis of rs13050728 Using information from all GTEx V8 tissues we identified 476 genes whose expression levels were associated with rs13050728 at a nominal significance level (P < 0.05). Taking into consideration an adjusted P value for multiple testing within the WikiPathway corpus, only two biological pathways were significantly associated among all 624 pathways present in this database: Host-pathogen interaction of human corona viruses - IFN induction (adjusted P value = 0.0028) and Type I IFN Induction and Signaling During SARS-CoV-2 Infection (adjusted P value = 0.0098). In addition, among Gene Ontology (GO) and Reactome pathways, several gene sets were also significantly enriched. Notably, among enriched pathways were those related to IFN type I or antiviral response (Supplementary Figure 2A). ACE2 Angiotensin converting enzyme 2 (ACE2) converts angiotensin II into angiotensin (1-7) as part of the RAA system, and more importantly, is the viral receptor for SARS-CoV-2. We identified seven cis-eQTLs in seven tissues (Supplementary Table 10) for ACE2 which are strongly correlated ( $r^2 > 0.75$  in 1000G EUR, Supplementary Table 11) with rs4830976 being the eQTL in the region most strongly associated with COVID-19 hospitalization.

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

pQTLs for ACE2 Stepwise conditional analysis for plasma ACE2 measured by Olink revealed one pQTL, rs5935998 ( $P=1.4\times10^{-21}$ ), which is in high LD with a previously reported cis-pOTL (rs12558179) for ACE2 ( $r^2$ =0.89 in 1000G EUR)<sup>24</sup>, and a secondary suggestive signal (rs4646156,  $P = 3.20 \times 10^{-7}$ ). rs5935998 and rs4646156 are concordant in their effect on COVID-19 hospitalization (higher ACE2 levels corresponds to higher risk of COVID-19 hospitalization for both) resulting in a strong, positive MR association (MR beta-coefficient: 0.34; 95% CI: 0.17-0.51:  $P=8.1\times10^{-5}$ ). Although neither rs5935998 or rs4646156 strongly colocalized with COVID-19 hospitalization (PP.H4=0.49 for rs5935998, PP.H4=0.08 for rs4646156, Supplementary Figure 3), the two pOTLs, while statistically independent, are mildly correlated  $(r^2=0.2 \text{ in } 1000 \text{G EUR})$ , which can make colocalization difficult to interpret.<sup>25</sup> One possible explanation is that these two pQTLs confer an effect on COVID-19 hospitalization that converges on the rs4830976-LD-block, as both are moderately correlated with rs4830976  $(r^2=0.32 \text{ for rs}5935998, r^2=0.42 \text{ for rs}4646156 \text{ in } 1000\text{G EUR}, \text{Supplementary Figure 3})$ Phenome-wide scan of rs4830976 rs4830976 is associated (P<4×10<sup>-5</sup>) with and colocalized (PP.H4>0.8) with expression of nearby genes CA5B, CLTRN (also known as TMEM27), and VEGFD (Supplementary Table 12) in at least one tissue, indicating that this variant may be instrumenting on gene expression beyond ACE2. However, given the biological prior that ACE2 acts as the receptor of SARS-CoV-2, ACE2 is probably more likely than CA5B, CLTRN or VEGFD to be responsible for COVID-19 hospitalization. There were no other reported phenome-wide scan results at  $P < 4 \times 10^{-5}$  for

rs4830976, which is at least in part due to the lack of reported X-chromosome results from a large proportion of GWAS.

Pathway enrichment analysis of rs4830976

Exploring the landscape of genes differentially expressed according to genotype in GTEx V8, we observed 1397 genes differentially expressed at a nominal P value less than 0.05. Overrepresentation analysis identified 238 significantly enriched biological pathways among differentially expressed genes (Supplementary figure 2B). Among these, signaling by interleukins, regulation of cytokine production, and antigen processing and presentation, might prove biologically relevant in COVID-19 infection.

**DISCUSSION** 

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

To identify drug-repurposing opportunities to inform trials against COVID-19, we conducted a large-scale MR analysis of protein and gene expression data. We first updated the "actionable" genome to an enlarged set of 1,263 human proteins and provided evidence for 700 of these as targets for drugs with some potential relevance to COVID-19. By testing more than a thousand of these using several of the largest currently available human genetic datasets, we provide evidence for drug targets of type-I IFNs (IFNAR2) and ACE2 modulators (ACE2) as priority candidates for evaluation in randomized trials of early management in COVID-19.

Our finding that ACE2 may play an important role in COVID-19 is unsurprising given its wellknown relevance to SARS-CoV-2. Since ACE2 acts as the primary receptor for SARS-CoV-2, increased expression of ACE2 has been hypothesized to lead to increased susceptibility to infection. ACE2 plays a vital role in the RAAS signaling pathway, providing negative regulation through the conversion of Angiotensin II to Angiotensin 1-7. This action has anti-inflammatory and cardioprotective effects<sup>26</sup> and plays a protective role in acute respiratory distress syndrome. 27,28 ACE2 is a single-pass membrane protein but can be cleaved from the membrane to a soluble form which retains the enzymatic function to cleave Angiotensin II. It has therefore been hypothesized that administration of human recombinant soluble ACE2 (hrsACE2) could be an effective treatment for COVID-19, through distinct mechanisms in two phases of COVID-19. First, hrsACE2 can bind the viral spike glycoprotein of SARS-CoV-2, which could prevent cellular uptake of SARS-CoV-2 by reducing binding to the membrane-bound form of ACE2 (early phase). This suggestion is supported by the finding that APN01, a hrsACE2 therapeutic, showed a 1000-5000 fold reduction in SARS-CoV-2 viral load in primate kidney epithelial (Vero) cells, as well as inhibiting infection of human blood vessel and kidney organoids.<sup>29</sup> In the

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

later phase, hrsACE2 could reduce sequelae of SARS-CoV-2 infection by reducing inflammation in the lungs and other infected tissues. A case report of a hospitalized COVID-19 patient supported this hypothesis by showing that 7-day administration of APN01 was associated with a reduction in SARS-CoV-2 viral load and inflammatory markers.<sup>30</sup> APN01 is currently being tested in a phase II trial to reduce mortality and invasive mechanical ventilation in 200 hospitalized COVID-19 patients<sup>31</sup>. One of the main challenges of our analysis was to determine whether IFNAR2 or IL10RB (or both) was driving the association with COVID-19 hospitalization, given that they share ciseOTLs used as proposed instruments for our MR analysis. Multiple lines of evidence indicate that IFNAR2 appears to be primarily responsible for the signal observed. First, our phenomewide scan using the lead IFNAR2/IL10RB cis-eQTL reproduced known effects of type-I IFNs (the therapeutic target of IFNAR2) on VEGFR2 and TPSG1. 20-22 Second, our pathway enrichment analysis using the same eQTL revealed pathways associated with type-I IFN receptor (IFNAR2) signaling. Last, three independent cis-pQTLs that are also cis-eQTLs for IL10RB did not show evidence of association with COVID-19, suggesting that plasma IL-10RB concentrations are unlikely to be etiologically relevant to COVID-19. Evidence of a role for type-I IFN in COVID-19 is rapidly emerging. Studies using *in vitro* (A549) pulmonary cell lines), animal (ferrets) and ex vivo (human lung tissue) models have all shown lower expression of genes encoding type-I IFNs after exposure to SARS-CoV-2 compared to other respiratory viruses. 32,33 This has been confirmed in vivo by studies showing significantly impaired type-I IFN response – including almost no IFN-beta activity - in the peripheral blood of severe COVID-19 patients compared to mild to moderate COVID-19 patients.<sup>34</sup> More

importantly, lower levels of IFN alpha-2 among recently hospitalized COVID-19 patients were associated with a substantial increase in the risk of progression to critical care, supporting our observation that lower genetically-predicted *IFNAR2* expression was associated with higher risk of COVID-19 hospitalization.<sup>34</sup> Additionally, auto-antibodies for type 1 IFNs were found in a much higher proportion of individuals with severe COVID-19 than those with asymptomatic or mild SARS-CoV-2 infection.<sup>35</sup>

Whole exome and genome sequencing studies on severe COVID-19 patients have identified rare mutations that implicate type I IFN signaling. Zheng et al.<sup>36</sup> found severe COVID-19 patients were enriched for rare variants predicted to cause loss of protein function at 13 genes involved in type-I IFN response. A cases-series of four severe COVID-19 patients under the age of 35 found a rare LOF mutation in *TLR7* and decreased type 1 IFN signaling.<sup>37</sup>

Several *in vitro* studies have shown that when diverse type of cells (including animal and human) and human organoids were pre-treated with type-I or -III IFNs, a reduction in SARS-CoV-2 replication was observed when compared with controls<sup>38-42</sup> (**Supplementary Table 13**). Though these *in vitro* studies are encouraging, the evidence from randomized trials for type I IFNs in early COVID-19 stages is limited. Hung et al.<sup>43</sup> showed that randomization to a combination of IFN beta-1b, ribavirin and lopinavir-ritonavir was superior to lopinavir-ritonavir alone in shortening the duration of viral shedding, alleviating symptoms and reducing the length of the hospital stay. Importantly, these benefits were confined to a subgroup who were hospitalized within 7 days of onset of symptoms where IFN beta-1b was administered to the intervention arm. These results, together with our genetic findings on COVID-19 hospitalization and the established role of type-I IFNs as first line of response against viral agents suggest recombinant

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

type-I IFN as potential intervention during early stages of COVID-19. To date, there is no large randomized trial on IFN beta for early treatment of COVID-19 patients who are at high risk of hospitalization. Trial evidence on the use of IFN-beta in late stages of COVID-19 has emerged in the last month. The SOLIDARITY trial, which randomized 2,050 hospitalized COVID-19 patients to IFN beta-1a, found no effect on mortality overall (relative risk (RR)=1.16, [95%CI: 0.96-1.39]), but possibly a trend across subgroups of COVID-19 severity at randomization (RR=1.40 [95%CI: 0.82-2.40] for those on ventilator, RR=1.13 [95%CI: 0.86-1.50] for those not ventilated but on oxygen, and RR=0.80 [95%CI: 0.27-2.35] in those with neither).<sup>44</sup> The Adaptive COVID-19 Treatment Trial 3 (ACTT-3) trial stopped enrollment of severely ill COVID-19 patients for a trial on IFN beta-1a and remdesivir due to adverse events but continued enrolling patients with less severe disease. 45 These findings indicate no role for the use of IFN beta during late stages of COVID-19, where the cytokine storm has already established. Our study has several strengths. We provide an updated catalog of all actionable protein targets and drugs that are amenable to causal inference investigation through human genetics. By combining several of the most comprehensive datasets currently available and linking genetic variation with gene expression, plasma protein levels and COVID-19, we were able to robustly evaluate over one thousand actionable drug targets. We took multiple steps to minimize potential biases and confounding that could invalidate our actionable druggable-genome-wide MR analysis, such as using colocalization methods to minimize the chances of false positive results due to confounding by LD. We were careful to reduce the impact of horizontal pleiotropy by restricting our proposed instruments to variants acting in cis and performing phenome-wide scan

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

early management of COVID-19.

to ensure they were only associated with gene expression of the tested gene or downstream phenotypes (vertical pleiotropy), but unmeasured sources can remain. Our analysis also has limitations. Though we make use of instrumental variants from multiple data sources, none cover the entire actionable druggable genome, were ancestry-specific or were derived from COVID-19 patients. However, we managed to recover credible biological targets from our analysis that were consistent across ancestral groups. Identifying the most relevant tissue or cell-type can be challenging for interpreting MR analyses of gene expression. In our case, a relevant tissue could be: one invaded by SARS-CoV-2, an organ associated with clinical complications of COVID-19, a tissue where the COVID-19-relevant protein is produced, or a tissue that would be the likely site of action for the target drug. We opted to use a data-driven strategy that incorporates all tissues available in GTEx V8. For IFNAR2, we recovered fibroblasts (the main cell type responsible for IFN-beta production), esophageal mucosa<sup>46,47</sup> (a tissue invaded by SARS-CoV-2), and skeletal muscle<sup>48</sup> (associated with the neurological manifestations of COVID-19). For ACE2, we recovered brain tissue, an organ known to be invaded by SARS-CoV-2 and associated with clinical manifestations. 49,50 In conclusion, our trans-ancestry MR analysis covering all actionable druggable genes identified two drug repurposing opportunities (type-I IFNs and hsrACE2) as interventions that need to be evaluated in adequately powered randomized trials to investigate their efficacy and safety for

**METHODS** 

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

Identification of actionable druggable genes suitable for repurposing against COVID-19 Information about drugs and clinical candidates, and their therapeutic targets, was obtained from the ChEMBL database (release 26<sup>51</sup>, **Supplementary Methods**). For the purposes of our COVID-19 drug repurposing efforts, actionable proteins were defined as those that are therapeutic targets of approved drugs and clinical candidates or are potential targets of approved drugs. Therapeutic targets were identified from the drug mechanism of action information in ChEMBL and linked to their component proteins. Each protein was assigned a confidence level based on the type and size of target annotated, and the resulting list was filtered to remove nonhuman proteins and those with lower confidence assignments (cases where the therapeutic target consists of more than 10 proteins or the protein is known to be a non-drug-binding subunit of a protein complex). For approved drugs, additional potential human target proteins were identified from pharmacological assay data in ChEMBL with recorded affinity/efficacy measurements <= 100nM (represented by a pChEMBL value >= 7). A total of 1,263 unique human proteins were identified as 'actionable' from data available in ChEMBL. These consisted of 531 proteins that are therapeutic targets of approved drugs, 381 additional proteins that are therapeutic targets of clinical candidates and 351 additional proteins that are bound by approved drugs, but not annotated as the therapeutic targets. While the biological relevance of the latter group of targets in the context of the approved drug indications may be unclear, the high affinity/efficacy measurements suggest the drug should be capable of modulating these proteins, should they be found to be relevant to COVID-19 (although likely not in a selective manner). Proteins were further annotated with biological and drug information relating to their potential role in SARS-CoV-2 infection (Supplementary methods) such as

change in abundance during infection, interaction with viral proteins or the activity of drugs in antiviral cell-based assays. Of the 1,263 actionable proteins identified previously, 300 were annotated as biologically relevant in SARS-CoV-2 infection and 547 were targets of drugs with some evidence of COVID-19 relevance from cell-based assays, clinical trials or the ATC classification (**Supplementary Table 2**).

# **Selection of proposed instruments**

eQTL proposed instruments

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

We proposed eQTL instruments using raw data from GTEx Version 8 by performing conditional analysis on normalized gene expression in European ancestry individuals in 49 tissues that had at least 70 samples. We used Matrix eOTL<sup>52</sup> and followed the same procedure as outlined by the GTEx consortium (https://gtexportal.org/home/). Briefly, after filtering the genotypes (genotype missingness <0.05, MAF<0.01, HWE<0.000001, removing ambiguous SNPs), within each tissue, we performed GWAS between variants and gene expression adjusting for sex, the first 5 principal components of European genetic ancestry, PEER factors, sequencing platform and protocol. To identify independent eQTLs, we performed conditional analysis in regions around associations that fell below genome-wide significance, additionally adjusting for the peak variant if there exists an association reaching a P-value of  $5\times10^{-8}$ . Cis-eQTLs were defined as significant  $(P < 5 \times 10^{-8})$  associations within 1Mb on either side of the encoded gene. To convert from build 38 to build 37, we used the table available from the GTEx consortium for all variants genotyped in **GTEx** v8 hg19 and liftover, (https://storage.googleapis.com/gtex analysis v8/reference/GTEx Analysis 2017-06-

05 v8 WholeGenomeSeg 838Indiv Analysis Freeze.lookup table.txt.gz).

tissue.

In

multiple GW-significant ( $P < 5 \times 10^{-8}$ ) eQTLs for the same gene were combined into a single instrument. For example, for *IL10RB* expression in skeletal muscle tissue, there were two conditionally-independent eQTLs (rs2300370 and rs2834167, **Table 1**) that made up that instrument.

# pQTL proposed instruments

We proposed pQTL instruments from two sources of publicly available data that reported conditionally independent pQTLs for proteins measured by the SomaLogic Inc. (Boulder, Colorado, US) SomaScan<sup>53,54</sup> platform: (1) Sun *et al.*<sup>15</sup>, which reported results for 2,994 proteins in 3,301 INTERVAL participants and (2) Pietzner *et al.*<sup>16</sup>, which reported results for 179 proteins in 10,708 participants of the Fenland. In both, we restricted proposed instrumental variants to *cis*-pQTLs for actionable proteins, used a P value threshold of  $5\times10^{-8}$  and removed variants with MAF<0.01. MR was run independently for each data source (i.e. proposed instruments for the same protein in different platforms were tested against COVID-19 hospitalization independently).

# **Estimates for COVID-19 hospitalization**

To generate outcome summary-statistics, we meta-analyzed results from the Million Veteran Program (MVP), an ongoing, prospective cohort recruiting from 63 Veterans Health Administration (VA) medical facilities (**Supplementary Methods**), and the Host Genetics Initiative, <sup>10</sup> a global collaboration to accumulate GWAS on COVID-19 infection and clinical manifestations.

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

In MVP, 1,062 COVID-19 cases (Supplementary Table 1) were identified between March 1st and September 17, 2020 using an algorithm developed by the VA COVID National Surveillance Tool (NST). The NST classified COVID-19 cases as positive or negative based on reverse transcription polymerase chain reaction (rRT-PCR) laboratory test results conducted at VA clinics, supplemented with Natural Language Processing (NLP) on clinical documents. The algorithm to identify COVID-19 patients is continually updated to ensure new annotations of COVID-19 are captured from the clinical notes, with chart reviews performed periodically to validate the algorithm.<sup>55</sup> COVID-19-related hospitalizations were defined as admissions from 7 days before up to 30 days after a patient's first positive test for SARS-CoV-2 test. We tested association between all our proposed genetic instruments and COVID-19 hospitalization (versus population controls) in MVP adjusting for age, sex and the first 10 principal components in ancestry-specific strata using PLINK v2 (analysis completed on October 10, 2020). The MVP received ethical and study protocol approval by the Veterans Affairs Central Institutional Review Board and informed consent was obtained for all participants. We downloaded publicly available summary statistics for the B2 outcome from Host Genetic Initiative on October 4, 2020 (release 4 version 1). In total, HGI accumulated 6,492 cases of COVID-19 hospitalization through collaboration from 16 contributing studies (Supplementary **Table 1**), which were asked to define cases as "hospitalized laboratory confirmed SARS-CoV-2 infection (RNA and/or serology based), hospitalization due to corona-related symptoms" versus population controls (https://docs.google.com/document/d/1okamrqYmJfa35ClLvCt vEe4PkvrTwggHq7T3ibevCI/vi ew) and use a model that adjusts for age, age<sup>2</sup>, sex, age\*sex, PCs, and study specific covariates (https://docs.google.com/document/d/16ethjgi4MzlQeO0KAW\_vDYvUHdB9kKbtfuGW4XYV

<u>KQg/view</u>) Results for each ancestry-stratum were meta-analyzed along with the HGI (summary statistics already meta-analyzed from contributing studies) for COVID hospitalization using METAL software<sup>56</sup> with inverse-variance weighting and fixed effects.

# Mendelian randomization and colocalization

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

We conducted MR the TwoSampleMR analyses using R package (https://mrcieu.github.io/TwoSampleMR/). We used fixed-effects, inverse-variance weighted MR for proposed instruments that contain more than one variant, and Wald-ratio for proposed instruments with one variant. For proposed instruments with multiple variants, we also tested the heterogeneity across variant-level MR estimates, using the Cochrane O (mr heterogeneity option in TwoSampleMR package). We defined significant MR results using a P value threshold of  $P < 4.0 \times 10^{-5}$  (0.05 Bonferroni-corrected for 1,263 actionable druggable genes) and identified a list of "suggestive" actionable druggable targets that passed a threshold of  $P < 5 \times 10^{-4}$ . For statistically significant MR results, we also performed colocalization<sup>57</sup> between each eOTL and the trans-ancestry meta-analysis on COVID-19 hospitalization using the moloc R package (https://github.com/clagiamba/moloc) with default priors (probability of shared causal variant for trait 1 and trait 2 is  $p1=p2=1\times10^{-4}$ , probability of shared causal variant across two traits is p12=1×10<sup>-5</sup>). For example, if a proposed instrument contained two variants, we performed colocalization for the primary eQTL GWAS with COVID-19 hospitalization, as well as the secondary eQTL GWAS (i.e. eQTL GWAS after adjusting for peak variant from primary GWAS) with COVID-19 hospitalization. Statistically significant MR hits with posterior probability for hypothesis-4 (PP.H4) > 0.8 (i.e. the probability of a shared causal variant) for a least one instrumental variant were then investigated further using the following analyses.

Identifying pQTLs using Olink assay

We performed stepwise conditional analysis to identify *cis*-pQTL proposed instruments for proteins that passed our significance and colocalization thresholds and were one of 354 unique proteins measured on four Olink<sup>58</sup> panels (CVD1, CVD2, Inflammation, and Neuro<sup>59</sup>) in 4,998 INTERVAL participants.<sup>15</sup> INTERVAL is a prospective cohort study of ~50,000 blood donors recruited from 25 National Health Service Blood and Transplant centers in England. Participants were genotyped using the UK Biobank Affymetrix Axiom array, followed by phasing using SHAPEIT3 and imputation on the Sanger Imputation Server using a 1000 Genomes Phase 3-UK10K imputation panel. Alleles were tested against Olink proteins using SNPTEST v2.5.2 and adjusted for age, sex, plate, time from blood draw to processing, season and the first 5 principal components. Conditional analysis was performed by adjusting for peak variants until no association fell below 5×10<sup>-6</sup>.

# Phenome-wide scan

We conducted a phenome-wide scan for variants with the following goals. First, we want to evaluate that our proposed instruments could reproduce the known phenotype associations (e.g. disease, biomarkers) ascribed to the drug that are due to on-target effects. Secondly, we want to identify if our proposed instruments are associated with comorbidities associated with greater likelihood of SARS-CoV-2 testing or predictors of hospitalization in COVID-19 patients, as this could potentially highlight the presence of certain biases.<sup>23</sup> Also, for genes that were the target of licensed drugs, we checked whether the disease indication was also a risk factor for COVID-19 outcomes, as this might introduce a bias analogous to confounding by indication in MR.

To accomplish these goals, we investigated proposed instruments for associations of a phenomewide range of outcomes. We searched the GTEx<sup>14</sup> Portal (<a href="https://gtexportal.org/home/">https://gtexportal.org/home/</a>) for gene expression, and Phenoscanner<sup>19</sup> (<a href="http://www.phenoscanner.medschl.cam.ac.uk/">http://www.phenoscanner.medschl.cam.ac.uk/</a>) for proteins, traits and diseases. We additionally queried variants in 354 Olink proteins data that have not been made publicly available (described earlier), and proteins measured by the SomaScan platform not previously published in Sun *et al.*<sup>15</sup>

# Characterizing downstream transcriptional consequences of associated loci

In order to confirm the specificity of the identified loci and to better explore their most important downstream transcriptional consequences, we have studied the transcriptional landscape modulation associated with the selected variants using GTEx V8 data with representation of 49 different tissues. For this we have used rs13050728 as the proxy of the *IFNAR2/IL10RB* locus and rs4830976 as the proxy of the *ACE2* locus and conducted a differential gene-expression analysis for all transcripts available in GTEx V8. After fitting models for all genes, enrichment pathway analysis was conducted to retrieve the most enriched pathways using both the differentially expressed (DE) gene list (through an over-representation analysis) and a Gene Set Enrichment Analysis framework (using the R package clusterProfiler<sup>60</sup>). For enrichment analysis we have used the corpus from WikiPathways, Gene Ontology and Reactome.

**Author contribution** 

J.P.C., A.S.B. and J.M.G. conceived the study design. A.G., A.P.B. and A.R.L. defined the actionable genome, and identified and curated drug information relating to SARS-CoV-2; P.B. and I.B.-H. provided biological annotation relating to SARS-CoV-2; C.G. performed stepwise conditional analysis on GTEx raw data; D.P. tested associations for COVID-19 in MVP; L.G. and J.H.Z. performed meta-analysis of HGI and MVP; L.G. performed Mendelian randomization analysis; L.G. and C.G. performed colocalization analyses; L.G. and B.P.P. performed conditional analysis on Olink proteins; L.G. and E.A. performed phenome-wide scans; A.C.P. performed pathway enrichment analysis; J.N.D., A.S.B., and J.E.P. provided INTERVAL data; Several authors were involved in the curation of the MVP data; L.G., C.G., A.C.P., A.G., D.P., A.S.B. and J.P.C. wrote the manuscript. J.P.C. oversaw all analyses. All authors critically reviewed the manuscript.

# Data availability

- Full MR results can be found on dbGAP in the VA Million Veteran Program space (accession:
- 616 phs001672).

### 617 Competing interests

The authors declare no competing interests.

# Acknowledgements

We are grateful to the Host Genetic Initiative for making their data publicly available (full acknowledgements can be found here: <a href="https://www.covid19hg.org/acknowledgements/">https://www.covid19hg.org/acknowledgements/</a>). This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award #MVP035. This research was also supported by additional Department of Veterans Affairs awards grant #MVP001. This publication does not represent the views of the Department of Veteran Affairs or

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

the United States Government. Full acknowledgements for the VA Million Veteran Program COVID-19 Science Initiative can be found in the supplementary methods. C.G. has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 754490 – MINDED project. A.G., P.B. and A.R.L. are funded by the Member States of the European Molecular Biology Laboratory (EMBL). I.B.-H. received funding from Open Targets (grant agreement OTAR-044). The Fenland Study (10.22025/2017.10.101.00001) is funded by the Medical Research Council (MC UU 12015/1); we are grateful to all the volunteers and to the General Practitioners and practice staff for assistance with recruitment; we thank the Fenland Study Investigators, Fenland Study Coordination team and the Epidemiology Field, Data and Laboratory teams; we further acknowledge support for genomics from the Medical Research Council (MC PC 13046); proteomic measurements were supported and governed by a collaboration agreement between the University of Cambridge and Somalogic. J.E.P. is supported by UKRI Innovation Fellowship at Health Data Research UK (MR/S004068/2). L.R., N.H. and C.L. are supported by the Swedish Research Council.

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

**Figure Legends** Figure 1. Outline of the analyses performed. Using multiple data sources, this study tested cispQTL and cis-eQTL proposed instruments for actionable druggable proteins against COVID-19 hospitalization summary statistics meta-analyzed from the Host Genetics Initiative and the Million Veteran program. Significant MR associations that also showed evidence for colocalization were investigated further with an independent platform (Olink), phenome-wide scans of relevant variants, and pathway enrichment. Figure 2. Manhattan plot of results from actionable druggable genome-wide Mendelian randomization analysis. Blue solid line indicates the P value threshold for significance (P <4.0x10<sup>-5</sup>, 0.05 Bonferroni-corrected for 1,263 actionable druggable genes) and red dashed line indicates the suggestive  $(P \le 5 \times 10^{-4})$  threshold. Genes are labeled by their most significant MR association. For example, the results for *IL10RB* is most significant with *cis*-eQTL proposed instruments derived in skeletal muscle tissue, which is the point labeled. Results are plotted by the gene start position. All MR results with P value less than  $5\times10^{-4}$  used the GTEx cis-eOTLs as proposed instruments. Figure 3. Genomic context, local association plot and LD structure of the IFNAR2/IL10RB **region.** A, Local association plot of the interval defined by all unique eOTLs for *IL10RB* or IFNAR2. Color code represents the degree of linkage disequilibrium with the most associated marker in 1000G Europeans. **B**, Genomic context of the region. Coding genes are represented by the refseq transcript. Bars represent epigenome Roadmap layered H3K27 acetylation markers. Connecting lines represent significant Hi-C interactions. C. Set of rsIDs used as proposed

instruments for Mendelian Randomization analysis. Color code represents instruments for *IL10RB* (blue circles), *IFNAR2* (green circles). Red half-circles represent pQTLs for IL-10RB. **D**Linkage disequilibrium structure and blocks defined using European populations from 1000G project. **Figure 4. Regional association plots of the** *IFNAR2-IL10RB* locus. Regional association plots for **A**, *IL10RB* gene expression in tibial nerve tissue from GTEx, **B** COVID-19 hospitalization from HGI and MVP trans-ancestry meta-analysis, **C**, **D**, Vascular endothelial growth factor receptor 2 (VEGFR2) and tryptase Gamma (TPSG1), respectively, measured by SomaLogic in 3,301 INTERVAL participants. All show the correlation (1000G European ancestry) for rs13050728, the *cis*-eQTL most associated with COVID-19 hospitalization in the *IL10RB*-I*FNAR2* region. All colocalize with each other (PP.H4>0.96 for all).

Figure 1.





Figure 2.




Tissue	beta	S.E.	P value	$oldsymbol{P_{ m het}}$	Variants in instrument	Colocalization
Muscle Skeletal	0.5081	0.0664	1.93E-14	0.9732	rs2300370, rs2834167	0.98, < 0.01
Nerve Tibial	0.2861	0.0383	8.15E-14	0.0052	rs13050728, rs2834167, rs2266590	0.98, <0.01, <0.01
Cells Cultured fibroblasts	0.4449	0.0612	3.60E-13	NA	rs13095940	<0.01
Brain Nucleus accumbens basal ganglia	0.2535	0.0361	2.18E-12	0.0019	rs2834167, rs17860115	0.75, 0.98
Brain Caudate basal ganglia	0.2628	0.0395	3.05E-11	0.0003	rs2834167, rs1051393	0.01, 0.97
Muscle Skeletal	0.5881	0.0909	9.75E-11	NA	rs2300370	0.98
Brain Cerebellar Hemisphere	0.1403	0.0227	6.87E-10	0.0389	rs2834167, rs2236758	0.01, 0.95
Breast Mammary Tissue	0.6490	0.1079	1.82E-09	NA	rs12053666	0.95
Brain Frontal Cortex BA9	0.1926	0.0326	3.33E-09	0.0366	rs2834167, rs1131668	0.14, 0.97
Brain Cortex	0.1773	0.0300	3.43E-09	0.0354	rs2834167, rs1131668	0.02, 0.96
Esophagus Gastroesophageal Junction	0.4667	0.0790	3.55E-09	NA	rs13059906	0.05
Brain Cerebellum	0.1146	0.0196	4.86E-09	0.0239	rs2834167, rs1131668	<0.01, 0.96
Esophagus Mucosa	0.4338	0.0751	7.60E-09	NA	rs34059564	<0.01
Esophagus Mucosa	-0.5420	0.0965	1.98E-08	NA	rs11911133	0.92
Artery Aorta	-0.4826	0.0861	2.11E-08	0.0202	rs370630099, rs45524632	0.41, 0.61
Testis	0.7104	0.1364	1.92E-07	NA	rs2284550	0.11
Skin not Sun Exposed Suprapubic	-0.3360	0.0671	5.46E-07	NA	rs8127500	<0.01
Pancreas	-0.4708	0.0957	8.63E-07	NA	rs1476415	0.06
Brain Frontal Cortex BA9	0.1121	0.0233	1.56E-06	NA	rs4830976	0.95
Cells Cultured fibroblasts	-0.3893	0.0819	1.98E-06	NA	rs1131668	0.92
Cells Cultured fibroblasts	-0.5197	0.1093	1.98E-06	NA	rs1131668	0.96
Lung	-0.5868	0.1272	3.99E-06	NA	rs12639314	0.02
Esophagus Gastroesophageal Junction	0.4678	0.1052	8.80E-06	NA	rs56079299	0.96
	Muscle Skeletal Nerve Tibial  Cells Cultured fibroblasts  Brain Nucleus accumbens basal ganglia Brain Caudate basal ganglia Muscle Skeletal Brain Cerebellar Hemisphere Breast Mammary Tissue Brain Frontal Cortex BA9 Brain Cortex Esophagus Gastroesophageal Junction Brain Cerebellum Esophagus Mucosa Esophagus Mucosa Artery Aorta Testis Skin not Sun Exposed Suprapubic Pancreas Brain Frontal Cortex BA9 Cells Cultured fibroblasts Cells Cultured fibroblasts Lung	Muscle Skeletal0.5081Nerve Tibial0.2861Cells Cultured fibroblasts0.4449Brain Nucleus accumbens basal ganglia0.2535Brain Caudate basal ganglia0.2628Muscle Skeletal0.5881Brain Cerebellar Hemisphere0.1403Breast Mammary Tissue0.6490Brain Frontal Cortex BA90.1926Brain Cortex0.1773Esophagus Gastroesophageal Junction0.4667Brain Cerebellum0.1146Esophagus Mucosa0.4338Esophagus Mucosa-0.5420Artery Aorta-0.4826Testis0.7104Skin not Sun Exposed Suprapubic-0.3360Pancreas-0.4708Brain Frontal Cortex BA90.1121Cells Cultured fibroblasts-0.3893Cells Cultured fibroblasts-0.5197Lung-0.5868	Muscle Skeletal         0.5081         0.0664           Nerve Tibial         0.2861         0.0383           Cells Cultured fibroblasts         0.4449         0.0612           Brain Nucleus accumbens basal ganglia         0.2535         0.0361           Brain Caudate basal ganglia         0.2628         0.0395           Muscle Skeletal         0.5881         0.0909           Brain Cerebellar Hemisphere         0.1403         0.0227           Breast Mammary Tissue         0.6490         0.1079           Brain Frontal Cortex BA9         0.1926         0.0326           Brain Cortex         0.1773         0.0300           Esophagus Gastroesophageal Junction         0.4667         0.0790           Brain Cerebellum         0.1146         0.0196           Esophagus Mucosa         0.4338         0.0751           Esophagus Mucosa         0.4338         0.0751           Estis         0.7104         0.1364           Skin not Sun Exposed Suprapubic         -0.3360         0.0671           Pancreas         -0.4708         0.0957           Brain Frontal Cortex BA9         0.1121         0.0233           Cells Cultured fibroblasts         -0.3893         0.0819           Cells Cultur	Muscle Skeletal         0.5081         0.0664         1.93E-14           Nerve Tibial         0.2861         0.0383         8.15E-14           Cells Cultured fibroblasts         0.4449         0.0612         3.60E-13           Brain Nucleus accumbens basal ganglia         0.2535         0.0361         2.18E-12 ganglia           Brain Caudate basal ganglia         0.2628         0.0395         3.05E-11           Muscle Skeletal         0.5881         0.0909         9.75E-11           Brain Cerebellar Hemisphere         0.1403         0.0227         6.87E-10           Breast Mammary Tissue         0.6490         0.1079         1.82E-09           Brain Frontal Cortex BA9         0.1926         0.0326         3.33E-09           Brain Cortex         0.1773         0.0300         3.43E-09           Esophagus Gastroesophageal Junction         0.4667         0.0790         3.55E-09           Brain Cerebellum         0.1146         0.0196         4.86E-09           Esophagus Mucosa         0.4338         0.0751         7.60E-09           Esophagus Mucosa         -0.5420         0.0965         1.98E-08           Artery Aorta         -0.4826         0.0861         2.11E-08           Testis         0.7104	Muscle Skeletal         0.5081         0.0664         1.93E-14         0.9732           Nerve Tibial         0.2861         0.0383         8.15E-14         0.0052           Cells Cultured fibroblasts         0.4449         0.0612         3.60E-13         NA           Brain Nucleus accumbens basal ganglia         0.2535         0.0361         2.18E-12         0.0019           Brain Caudate basal ganglia         0.2628         0.0395         3.05E-11         0.0003           Muscle Skeletal         0.5881         0.0909         9.75E-11         NA           Brain Cerebellar Hemisphere         0.1403         0.0227         6.87E-10         0.0389           Breast Mammary Tissue         0.6490         0.1079         1.82E-09         NA           Brain Frontal Cortex BA9         0.1926         0.0326         3.33E-09         0.0366           Brain Cortex         0.1773         0.0300         3.43E-09         0.0354           Esophagus Gastroesophageal Junction         0.4667         0.0790         3.55E-09         NA           Brain Cerebellum         0.1146         0.0196         4.86E-09         0.0239           Esophagus Mucosa         -0.4320         0.0965         1.98E-08         NA           Arte	Muscle Skeletal         0.5081         0.0664         1.93E-14         0.9732         rs2300370, rs2834167           Nerve Tibial         0.2861         0.0383         8.15E-14         0.0052         rs13050728, rs2834167, rs2266590           Cells Cultured fibroblasts         0.4449         0.0612         3.60E-13         NA         rs13095940           Brain Nucleus accumbens basal         0.2535         0.0361         2.18E-12         0.0019         rs2834167, rs17860115           ganglia         0.2628         0.0395         3.05E-11         0.0003         rs2834167, rs1051393           Muscle Skeletal         0.5881         0.0909         9.75E-11         NA         rs2300370           Brain Cerebellar Hemisphere         0.1403         0.0227         6.87E-10         0.0389         rs2834167, rs1051393           Breast Mammary Tissue         0.6490         0.1079         1.82E-09         NA         rs12053666           Brain Frontal Cortex BA9         0.1926         0.0326         3.33E-09         0.0366         rs2834167, rs1131668           Brain Cerebellum         0.1173         0.0300         3.43E-09         0.0354         rs2834167, rs1131668           Esophagus Gastroesophageal Junction         0.4667         0.0790         3.55E-09         NA </td


Significant Mendelian randomization results  $P < 4.0 \times 10^{-5}$ . All results used *cis*-eQTL instruments. No results using *cis*-pQTL instruments yielded results  $P < 5 \times 10^{-4}$ . P<sub>het</sub> refers to the heterogeneity P value across individual-variant MR estimates within a genetic instrument calculated using the Cochrane Q method, therefore instruments containing one variant were not tested for heterogeneity. A positive beta estimate indicates that more gene expression is associated with higher risk of COVID-19 hospitalization. "Colocalization" indicates PP.H4 between eQTLs and COVID-19 hospitalization. For example, for IL10RB in skeletal muscle, the primary GWAS with rs2300370 as the peak *cis*-eQTL colocalizes with COVID-19 hospitalization at PP.H4=0.98, and the secondary GWAS (i.e. after adjusting for rs2300370) with rs2834167 as the peak *cis*-eQTL does not colocalize with COVID-19 hospitalization (PP.H4<0.01).



686



687 Figure 4.



Position on chr21 (Mb)

Position on chr21 (Mb)

### References

688

- Horby, P., *et al.* Dexamethasone in Hospitalized Patients with Covid-19 Preliminary Report. *N Engl J Med* (2020).
- 691 2. Beigel, J.H., *et al.* Remdesivir for the Treatment of Covid-19 Final Report. *N Engl J Med* (2020).
- Nelson, M.R., *et al.* The support of human genetic evidence for approved drug indications. *Nat Genet* **47**, 856-860 (2015).
- Hingorani, A.D., *et al.* Improving the odds of drug development success through human genomics: modelling study. *Sci Rep* **9**, 18911 (2019).
- Cohen, J.C., Boerwinkle, E., Mosley, T.H., Jr. & Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med* 354, 1264-1272 (2006).
- 700 6. Lopalco, L. CCR5: From Natural Resistance to a New Anti-HIV Strategy. *Viruses* **2**, 701 574-600 (2010).
- 702 7. Finan, C., *et al.* The druggable genome and support for target identification and validation in drug development. *Sci Transl Med* **9**(2017).
- Swerdlow, D.I., *et al.* The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *Lancet* **379**, 1214-1224 (2012).
- Kleveland, O., *et al.* Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. *Eur Heart J* 37, 2406-2413 (2016).
- 710 10. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur J Hum Genet* **28**, 715-718 (2020).
- 713 11. Gaziano, J.M., *et al.* Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol* **70**, 214-223 (2016).
- 715 12. Swanson, S.A. & Hernán, M.A. Commentary: how to report instrumental variable analyses (suggestions welcome). *Epidemiology* **24**, 370-374 (2013).
- Tabrecque, J. & Swanson, S.A. Understanding the Assumptions Underlying Instrumental
   Variable Analyses: a Brief Review of Falsification Strategies and Related Tools. *Curr Epidemiol Rep* 5, 214-220 (2018).
- 720 14. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580-585 (2013).
- 721 15. Sun, B.B., *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73-79 (2018).
- 723 16. Pietzner, M., *et al.* Genetic architecture of host proteins interacting with SARS-CoV-2. *bioRxiv*, 2020.2007.2001.182709 (2020).
- 725 17. Borden, E.C., *et al.* Interferons at age 50: past, current and future impact on biomedicine. 726 *Nat Rev Drug Discov* **6**, 975-990 (2007).
- T27 18. Emilsson, V., *et al.* Co-regulatory networks of human serum proteins link genetics to disease. *Science* **361**, 769-773 (2018).
- 729 19. Staley, J.R., *et al.* PhenoScanner: a database of human genotype-phenotype associations. *Bioinformatics* **32**, 3207-3209 (2016).
- von Marschall, Z., *et al.* Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. *J Natl Cancer Inst* **95**, 437-448 (2003).

- Jia, H., *et al.* Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. *Thromb Res* **163**, 105-116 (2018).
- Casassus, P., *et al.* Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. *Br J Haematol* **119**, 1090-1097 (2002).
- 739 23. Swanson, S.A., Tiemeier, H., Ikram, M.A. & Hernán, M.A. Nature as a Trialist?:
   740 Deconstructing the Analogy Between Mendelian Randomization and Randomized Trials.
   741 Epidemiology 28, 653-659 (2017).
- 742 24. Nelson, C.P., *et al.* Genetic Associations With Plasma Angiotensin Converting Enzyme 2
  743 Concentration: Potential Relevance to COVID-19 Risk. *Circulation* **142**, 1117-1119
  744 (2020).
- 745 25. Wallace, C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. *PLoS Genet* **16**, e1008720 (2020).
- Hemnes, A.R., *et al.* A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension. *Eur Respir J* **51**(2018).
- 749 27. Kuba, K., Imai, Y., Rao, S., Jiang, C. & Penninger, J.M. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. *J Mol Med (Berl)* **84**, 814-820 (2006).
- Yang, P., *et al.* Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. *Sci Rep* **4**, 7027 (2014).
- 753 29. Monteil, V., *et al.* Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. *Cell* **181**, 905-913.e907 (2020).
- Zoufaly, A., et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet
   *Respir Med* (2020).
- 757 31. Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19. (https://ClinicalTrials.gov/show/NCT04335136).
- 32. Blanco-Melo, D., *et al.* Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* 181, 1036-1045.e1039 (2020).
- 761 33. Chu, H., et al. Comparative Replication and Immune Activation Profiles of SARS-CoV-2
   762 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the
   763 Pathogenesis of COVID-19. Clin Infect Dis 71, 1400-1409 (2020).
- Hadjadj, J., *et al.* Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science* **369**, 718-724 (2020).
- 766 35. Bastard, P., et al. Auto-antibodies against type I IFNs in patients with life-threatening
   767 COVID-19. Science (2020).
- 768 36. Zhang, Q., *et al.* Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* (2020).
- van der Made, C.I., *et al.* Presence of Genetic Variants Among Young Men With Severe COVID-19. *Jama* **324**, 1-11 (2020).
- 772 38. Lokugamage, K.G., *et al.* SARS-CoV-2 is sensitive to type I interferon pretreatment. *bioRxiv* (2020).
- 774 39. Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S. & Huang, C. Antiviral activities of type I interferons to SARS-CoV-2 infection. *Antiviral Res* **179**, 104811 (2020).
- Stanifer, M.L., *et al.* Critical Role of Type III Interferon in Controlling SARS-CoV-2
   Infection in Human Intestinal Epithelial Cells. *Cell Rep* 32, 107863 (2020).

- Clementi, N., *et al.* Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 In Vitro When Administered After Virus Infection. *J Infect Dis* 222, 722 725 (2020).
- 781 42. Dinnon, K.H., *et al.* A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-782 19 medical countermeasures. *bioRxiv*, 2020.2005.2006.081497 (2020).
- Hung, I.F., *et al.* Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet* **395**, 1695-1704 (2020).
- Pan, H., *et al.* Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results. *medRxiv*, 2020.2010.2015.20209817 (2020).
- 788 45. NIAID Stops COVID-19 Trial Enrollment Over Adverse Events. (2020).
- 789 46. Xiao, F., et al. Evidence for Gastrointestinal Infection of SARS-CoV-2.
   790 Gastroenterology 158, 1831-1833.e1833 (2020).
- 791 47. Bradley, B.T., *et al.* Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. *Lancet* **396**, 320-332 (2020).
- 793 48. Mao, L., *et al.* Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol* **77**, 683-690 (2020).
- 795 49. Puelles, V.G., *et al.* Multiorgan and Renal Tropism of SARS-CoV-2. *N Engl J Med* **383**, 590-592 (2020).
- 797 50. Song, E., *et al.* Neuroinvasion of SARS-CoV-2 in human and mouse brain. *bioRxiv*, 2020.2006.2025.169946 (2020).
- 799 51. Mendez, D., *et al.* ChEMBL: towards direct deposition of bioassay data. *Nucleic Acids* 800 *Res* **47**, D930-d940 (2019).
- Shabalin, A.A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. *Bioinformatics* **28**, 1353-1358 (2012).
- 803 53. Rohloff, J.C., *et al.* Nucleic Acid Ligands With Protein-like Side Chains: Modified
  804 Aptamers and Their Use as Diagnostic and Therapeutic Agents. *Mol Ther Nucleic Acids*805 **3**, e201 (2014).
- 606 54. Gold, L., *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS One* **5**, e15004 (2010).
- Chapman, A.B., *et al.* A Natural Language Processing System for National COVID-19
   Surveillance in the US Department of Veterans Affairs. (2020).
- Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-2191 (2010).
- 612 57. Giambartolomei, C., *et al.* A Bayesian framework for multiple trait colocalization from summary association statistics. *Bioinformatics* **34**, 2538-2545 (2018).
- Lundberg, M., Eriksson, A., Tran, B., Assarsson, E. & Fredriksson, S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. *Nucleic Acids Res* **39**, e102 (2011).
- 817 59. Olink Target 96 & Target 48 panels for protein biomarker discovery.

820

Yu, G., Wang, L.G., Han, Y. & He, Q.Y. clusterProfiler: an R package for comparing biological themes among gene clusters. *Omics* **16**, 284-287 (2012).